Revive Therapeutics Ltd. (RVV.CN)
CAD 0.01
(-50.0%)
CAD 0.01
(-50.0%)
| Breakdown | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -3.29 Million | -6.02 Million | -13.06 Million | -8.3 Million | -2.51 Million | -1.18 Million |
| Net Income | -5.61 Million | -6.32 Million | -17.8 Million | -20.11 Million | -5.38 Million | -1.34 Million |
| Depreciation & Amortization | 328.00 | 434.00 | 578.00 | 775.00 | 28.26 Thousand | 3201.00 |
| Deferred income taxes | - | - | - | 1.55 Million | 1.64 Million | - |
| Stock-based compensation | - | - | 1.03 Million | 8.56 Million | 1.19 Million | 133.23 Thousand |
| Change in working capital | -185.53 Thousand | -747.61 Thousand | 3.54 Million | 705.74 Thousand | -502.98 Thousand | -4848.00 |
| Other non-cash items | 2.51 Million | 1.04 Million | 167.35 Thousand | 982.14 Thousand | 502.64 Thousand | 27.38 Thousand |
| Investing Cash Flow | - | - | - | -2.71 Million | 142.24 Thousand | -750.68 Thousand |
| Investments in PPE | - | 2.00 | - | -3 Million | - | -685.00 |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | -750 Thousand |
| Sales/Maturities of investments | - | - | - | 281.34 Thousand | 142.24 Thousand | - |
| Other Investing Activities | - | - | - | -2718.65 | 142.24 | -750.69 |
| Financing Cash Flow | 1.97 Million | 4.19 Million | 376.35 Thousand | 26.24 Million | 3.27 Million | 1.35 Million |
| Debt repayment | -40 Thousand | -152.03 Thousand | -151.53 Thousand | -148.99 Thousand | -136.18 Thousand | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 2.01 Million | 4.19 Million | 376.15 Thousand | 28.66 Million | 3.39 Million | 1.35 Million |
| Other Financing Activities | - | 152.03 Thousand | 151.73 Thousand | -2.27 Million | 22.86 Thousand | 1350.32 |
| Accounts receivables | 10.64 Thousand | 59.73 Thousand | -45.2 Thousand | 67.5 Thousand | -100.79 Thousand | - |
| Accounts payables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Other working capital | -196.18 Thousand | -807.34 Thousand | 3.58 Million | 638.23 Thousand | -402.19 Thousand | -4848.00 |
| Cash at beginning of period | 2.13 Million | 3.91 Million | 16.59 Million | 1.38 Million | 475.23 Thousand | 1.06 Million |
| Cash at end of period | 823.06 Thousand | 2.08 Million | 3.91 Million | 16.59 Million | 1.38 Million | 475.23 Thousand |
| Capital Expenditure | - | 2.00 | - | -3 Million | - | -685.00 |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | -1.31 Million | -1.82 Million | -12.68 Million | 15.21 Million | 906.24 Thousand | -585.28 Thousand |
| Free Cash Flow | -3.29 Million | -6.02 Million | -13.06 Million | -11.3 Million | -2.51 Million | -1.18 Million |
| Breakdown | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 FY | 2022 Q4 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -2.58 Million | -1.87 Million | -770.62 Thousand | -390.62 Thousand | -6.32 Million | -1.19 Million |
| Depreciation & Amortization | 82.00 | 82.00 | 82.00 | 82.00 | 434.00 | 109.00 |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | 136.45 | - | - | - | - |
| Change in working capital | -1825.00 | 75.82 Thousand | -152.42 Thousand | -107.11 Thousand | -747.61 Thousand | -239.65 Thousand |
| Other non-cash items | 2.31 Million | 174.49 Thousand | 39.54 Thousand | 2126.00 | 1.04 Million | 828.71 Thousand |
| Investing Cash Flow | 40 Thousand | -40 Thousand | - | - | - | - |
| Investments in PPE | -1.00 | 4.00 | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | 40 Thousand | -40 Thousand | - | - | - | - |
| Financing Cash Flow | -40 Thousand | 2.01 Million | 38.77 Thousand | -38.26 Thousand | 4.19 Million | 37.97 Thousand |
| Debt repayment | -40 Thousand | -38.77 | -38.77 Thousand | -38.26 Thousand | -152.03 Thousand | -38.01 |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | 2.01 Million | - | - | 4.19 Million | - |
| Other Financing Activities | - | 38.77 Thousand | 38.77 Thousand | 38.26 Thousand | 152.03 Thousand | 38 Thousand |
| Accounts receivables | 57.85 Thousand | -13.83 Thousand | -31.88 Thousand | -1493.00 | 59.73 Thousand | 35.51 Thousand |
| Accounts payables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Other working capital | -59.67 Thousand | 89.65 Thousand | -120.54 Thousand | -105.62 Thousand | -807.34 Thousand | -275.16 Thousand |
| Cash at beginning of period | 1.09 Million | 758.41 Thousand | 1.64 Million | 2.08 Million | 3.91 Million | 2.7 Million |
| Cash at end of period | 823.06 Thousand | 1.09 Million | 758.41 Thousand | 1.59 Million | 2.08 Million | 2.13 Million |
| Capital Expenditure | -1.00 | 4.00 | - | - | - | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | -276.32 Thousand | 340.98 Thousand | -883.41 Thousand | -495.52 Thousand | -1.82 Million | -568.09 Thousand |
| Free Cash Flow | -276.33 Thousand | -1.63 Million | -883.41 Thousand | -495.52 Thousand | -6.02 Million | -568.09 Thousand |
ASY
OCUL
NUAG
RCAR
3962
DUKB